|
|
|
Insider
Information: |
Goeddel David V |
Relationship: |
10% Owner |
City: |
So. San Francisco |
State: |
CA |
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
9 |
|
Direct
Shares |
21,008,913 |
|
Indirect Shares
|
32,725,451 |
|
|
Direct
Value |
$111,094,577 |
|
|
Indirect Value
|
$153,393,180 |
|
|
Total
Shares |
53,734,364 |
|
|
Total
Value |
$264,487,757 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
63
|
4
|
Stock
price went up :
|
24
|
1
|
Stock
price went down : |
39
|
3
|
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
Percentage
Gain/Loss : |
-0.2%
|
-73.3%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Immune Design Corp. |
IMDZ |
10% Owner |
2016-09-20 |
3,961,942 |
2014-07-29 |
0 |
Premium* |
|
Gritstone Oncology, Inc. |
GRTS |
Managing Partner |
2018-10-02 |
3,102,934 |
2018-10-02 |
0 |
Premium* |
|
Ngm Biopharmaceuticals Inc |
NGM |
Director, 10% Owner |
2024-04-05 |
0 |
2024-04-05 |
1,000 |
Premium* |
|
Rapt Therapeutics, Inc. |
RAPT |
Managing Partner, 10% ... |
2020-09-22 |
5,630,497 |
2019-11-04 |
195,401 |
Premium* |
|
Oric Pharmaceuticals, Inc. |
ORIC |
Managing Partner, 10% ... |
2020-04-28 |
4,768,181 |
|
0 |
Premium* |
|
Revolution Medicines, Inc. |
RVMD |
10% Owner |
2020-11-16 |
2,151,026 |
2020-11-16 |
3,799,202 |
Premium* |
|
Nurix Therapeutics, Inc. |
NRIX |
10% Owner |
2021-05-05 |
1,394,333 |
2021-05-05 |
1,420,954 |
Premium* |
|
Tenaya Therapeutics, Inc. |
TNYA |
|
2021-08-03 |
0 |
2024-02-12 |
22,999,565 |
Premium* |
|
Effector Therapeutics Ord Shs |
EFTR |
10% Owner |
|
0 |
2021-08-25 |
4,309,329 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
145 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 4 of 6
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
ORIC |
Oric Pharmaceuticals, Inc... |
10% Owner |
|
2020-04-23 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
75,000 |
|
- |
|
ORIC |
Oric Pharmaceuticals, Inc... |
Managing Partner |
|
2020-04-28 |
4 |
A |
$0.00 |
$0 |
D/D |
4,693,181 |
4,768,181 |
0 |
- |
|
RVMD |
Revolution Medicines, Inc... |
Managing Partner |
|
2020-06-17 |
4 |
A |
$0.00 |
$0 |
I/I |
7,234 |
7,234 |
0 |
- |
|
NGM |
Ngm Biopharmaceuticals In... |
Managing Partner |
|
2020-07-21 |
4 |
OE |
$13.35 |
$320,400 |
D/D |
24,000 |
44,000 |
0 |
- |
|
NGM |
Ngm Biopharmaceuticals In... |
Managing Partner |
|
2020-07-22 |
4 |
B |
$18.00 |
$3,474 |
D/D |
193 |
1,540,264 |
3.84 |
% |
|
NRIX |
Nurix Therapeutics, Inc. |
10% Owner |
|
2020-07-23 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
83,333 |
|
- |
|
NRIX |
Nurix Therapeutics, Inc. |
Managing Partner |
|
2020-07-28 |
4 |
A |
$0.00 |
$0 |
D/D |
6,672,548 |
686,274 |
0 |
- |
|
RAPT |
Rapt Therapeutics, Inc. |
Managing Partner |
|
2020-08-17 |
4 |
S |
$22.75 |
$12,254,379 |
D/D |
(538,654) |
4,443,679 |
0 |
% |
|
NGM |
Ngm Biopharmaceuticals In... |
Managing Partner |
|
2020-09-01 |
4 |
B |
$17.64 |
$643,754 |
D/D |
36,494 |
1,799,430 |
3.92 |
% |
|
NGM |
Ngm Biopharmaceuticals In... |
Managing Partner |
|
2020-09-02 |
4 |
B |
$17.67 |
$487,604 |
D/D |
27,595 |
1,827,025 |
3.92 |
% |
|
RAPT |
Rapt Therapeutics, Inc. |
Managing Partner |
|
2020-09-22 |
4 |
S |
$30.85 |
$18,756,800 |
D/D |
(608,000) |
3,835,679 |
0 |
% |
|
RVMD |
Revolution Medicines, Inc... |
10% Owner |
|
2020-11-16 |
4 |
S |
$36.40 |
$34,653,637 |
D/D |
(952,023) |
2,151,026 |
0 |
% |
|
RVMD |
Revolution Medicines, Inc... |
10% Owner |
|
2020-11-16 |
4 |
S |
$36.40 |
$39,134,841 |
I/I |
(1,075,133) |
2,429,180 |
0 |
% |
|
NRIX |
Nurix Therapeutics, Inc. |
General Partner |
|
2021-05-05 |
4 |
A |
$0.00 |
$0 |
I/I |
809,826 |
48,406 |
0 |
- |
|
NRIX |
Nurix Therapeutics, Inc. |
General Partner |
|
2021-05-05 |
4 |
D |
$0.00 |
$0 |
I/I |
(1,488,027) |
0 |
0 |
- |
|
NRIX |
Nurix Therapeutics, Inc. |
General Partner |
|
2021-05-05 |
4 |
D |
$0.00 |
$0 |
D/D |
(2,000,000) |
1,394,333 |
0 |
- |
|
TNYA |
Tenaya Therapeutics, Inc. |
Director |
|
2021-08-03 |
4 |
A |
$0.00 |
$0 |
I/I |
9,346,124 |
4,985,570 |
0 |
- |
|
EFTR |
Effector Therapeutics Ord... |
10% Owner |
|
2021-08-25 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
4,309,329 |
|
- |
|
NGM |
Ngm Biopharmaceuticals In... |
Director |
|
2022-01-24 |
4 |
B |
$0.00 |
$0 |
I/I |
250,000 |
8,250 |
2.17 |
% |
|
NGM |
Ngm Biopharmaceuticals In... |
Director |
|
2022-01-25 |
4 |
B |
$0.00 |
$0 |
I/I |
599,701 |
28,041 |
2.17 |
% |
|
NGM |
Ngm Biopharmaceuticals In... |
Director |
|
2022-05-09 |
4 |
B |
$10.79 |
$897,699 |
I/I |
83,175 |
30,786 |
2.25 |
% |
|
NGM |
Ngm Biopharmaceuticals In... |
Director |
|
2022-05-10 |
4 |
B |
$11.36 |
$355,283 |
I/I |
31,265 |
31,818 |
2.25 |
% |
|
NGM |
Ngm Biopharmaceuticals In... |
Director |
|
2022-05-11 |
4 |
B |
$11.23 |
$935,354 |
I/I |
83,175 |
34,563 |
2.25 |
% |
|
NGM |
Ngm Biopharmaceuticals In... |
Director |
|
2022-05-12 |
4 |
B |
$11.62 |
$966,678 |
I/I |
83,175 |
37,308 |
2.25 |
% |
|
NGM |
Ngm Biopharmaceuticals In... |
Director |
|
2022-05-13 |
4 |
B |
$0.00 |
$0 |
I/I |
129,365 |
41,577 |
2.17 |
% |
|
145 Records found
|
|
Page 4 of 6 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|